GREE, INC v. SUPERCELL OY

CourtDistrict Court, E.D. Texas
DecidedJanuary 29, 2020
Docket2:19-cv-00161
StatusUnknown

This text of GREE, INC v. SUPERCELL OY (GREE, INC v. SUPERCELL OY) is published on Counsel Stack Legal Research, covering District Court, E.D. Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
GREE, INC v. SUPERCELL OY, (E.D. Tex. 2020).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF TEXAS MARSHALL DIVISION

GREE, INC, § § Plaintiff, § § v. § CIVIL ACTION NO. 2:19-CV-00161-JRG-RSP § SUPERCELL OY, § § Defendant. §

MEMORANDUM OPINION AND ORDER Before the Court is Objection to Report and Recommendation (“the Objection”) filed by Defendant Supercell Oy (“Supercell”). (Dkt. No. 60). In the Objection, Supercell argues that the Magistrate Judge erred in entering a Report and Recommendation (“R&R”) (Dkt. No. 58), which recommended denying the Motion to Dismiss filed by Supercell (Dkt. No. 25). Plaintiff GREE, Inc. (“GREE”) has filed a response to Supercell’s Objection (“the Response”). (Dkt. No. 62). Having considered the briefing addressed to Supercell’s Motion to Dismiss as well as the R&R, Supercell’s Objection, GREE’s Response, and the totality of the record, the Court concludes that Supercell’s Objection is without merit for the reasons stated within the R&R. Further, as an independent basis for adopting the Magistrate Judge’s R&R, the Court finds that Supercell has failed to meet its burden to show that the claims discussed in the Motion to Dismiss are representative of the remaining claims in the Asserted Patents as to the issue of patent-eligible subject matter. I. Factual and Procedural Background In its First Amended Complaint (“the Complaint”) (Dkt. No. 10), GREE alleges that Supercell infringes U.S. Patent No. 10,286,318 (“the ’318 Patent”) and U.S. Patent No. 10,279,262 (“the ’262 Patent”) (collectively, “the Asserted Patents”). In its Motion to Dismiss, Supercell asks the Court to invalidate every claim in both Asserted Patents, as lacking patent-eligible subject matter, based solely on an analysis of the first claim in each Asserted Patent—Claim 1 of the ’318 Patent as well as Claim 1 of the ’262 Patent (“the Allegedly Representative Claims”). Supercell acknowledges that “[t]he ’318 [P]atent contains thirteen claims, three of which are independent”

and that “[t]he ’262 [P]atent contains 24 claims, four of which are independent.” (Dkt. No. 25 at 2). For the reasons set forth herein, the Court finds that Supercell has failed to meet its burden to demonstrate that the two claims discussed in the Motion to Dismiss are representative of all of the remaining thirty-five claims contained in the two Asserted Patents. II. Legal Standard Each claim in a patent is presumed independently valid. PPS Data, LLC v. Jack Henry & Assocs., Inc., 404 F. Supp. 3d 1021, 1030 (E.D. Tex. 2019) (citing 35 U.S.C. § 282). Accordingly, “when a defendant seeks to invalidate multiple claims based only on allegations relating to a subset of those claims, the defendant must justify treating that subset as representative of the other

claims.” Id. (citing Aqua Prod., Inc. v. Matal, 872 F.3d 1290, 1305 (Fed. Cir. 2017); 35 U.S.C. § 282(a)). “The party asserting invalidity may overcome the presumption of independent validity by offering a substantial rationale for treating a claim as representative of other asserted claims.” Id. However, “a claim is not representative merely because it generally deals with the same subject matter as the other asserted claims” or “simply because it is an independent claim” from which other claims depend. Id. at 1031 (citing Enfish, LLC v. Microsoft Corp., 822 F.3d 1327, 1337 (Fed. Cir. 2016); Berkheimer v. HP Inc., 881 F.3d 1360, 1365 (Fed. Cir. 2018), cert. denied, No. 18- 415, 2020 WL 129532 (U.S. Jan. 13, 2020)). Further, “[i]n general, claims in one patent will not represent claims in another patent because patents must contain distinct inventions.” Id. (citing Novartis Pharm. Corp. v. Breckenridge Pharm. Inc., 909 F.3d 1355, 1362 (Fed. Cir. 2018)) (“Since different patents must generally contain patentably distinct inventions, it follows that the claims in one patent will not usually represent all of the inventive concepts embodied in the claims of another patent.”). Instead, “to meet its burden, the defendant must conduct an analysis tethered to the claim language” of each claim for which a determination of invalidity is sought, and must

demonstrate “that there are no legally relevant distinctions between the claim identified as representative and the remaining asserted claims.” Id. at 1030–31 (citing Solutran, Inc. v. Elavon, Inc., 931 F.3d 1161, 1168 (Fed. Cir. 2019)). When a defendant meets its initial burden and “has proven a prima facie case demonstrating representativeness, the burden shifts to the plaintiff to identify limitations that are present in the asserted claims but that are not represented by the allegedly representative claim.” Id. at 1031–32. “[I]f the plaintiff identifies legally distinctive limitations, then any claims which contain those limitations are excluded from the scope of the relief sought by the defendant and must be distinctively addressed, typically in supplemental motion practice.” Id. at 1032 (citing Berkheimer,

881 F.3d at 1365; MaxLinear, Inc. v. CF CRESPE LLC, 880 F.3d 1373, 1377 (Fed. Cir. 2018)). III. Discussion In this case, Supercell has failed to meet its burden to demonstrate representativeness.1 Supercell analyzes only one claim in each of the Asserted Patents as a stand-in for a cumulative total of thirty-five other claims. Specifically, Supercell analyzes Claim 1 of the ’318 Patent as well as Claim 1 of the ’262 Patent (“the Allegedly Representative Claims”). However, Supercell’s Motion to Dismiss does not adequately address the issue of representativeness. For example,

1 Since Supercell has failed to meet its initial burden, the Court need not—and does not—reach whether GREE has identified “legally distinctive limitations.” See PPS Data, 404 F. Supp. 3d at 1036. Under the relevant burden-shifting framework, the burden only shifts to GREE to identify such limitations after Supercell had made its initial showing. See id. Supercell does not explain why either claim is representative, which claims are represented thereby, or how the Court could conclude that “there are no legally relevant distinctions” between the two claims Supercell discusses and the remaining thirty-five claims. See PPS Data, 404 F. Supp. 3d at 1036. Supercell claims that GREE has admitted in the Complaint that the Allegedly

Representative Claims are “representative” for all purposes. (Dkt. No. 25 at 3–4). However, a review of the Complaint reveals that such is not the case. The Complaint does discuss representativeness, but it does so exclusively in context of its infringement allegations. Specifically, the Complaint indicates that the Allegedly Representative Claims are representative of GREE’s infringement theories with regard to the manner in which Supercell’s products allegedly infringe. (See, e.g., Dkt. No. 10 ¶¶ 24, 26, 40). The surrounding context confirms that the Complaint’s discussion of the Allegedly Representative Claims was addressed only to infringement. After expressly indicating that the “infringement theories presented below are exemplary,” under two headers labeled “infringement,” the Complaint describes how Supercell’s

products meet each limitation of each of the Allegedly Representative Claims.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Adams Respiratory Therapeutics, Inc. v. Perrigo Co.
616 F.3d 1283 (Federal Circuit, 2010)
Enfish, LLC v. Microsoft Corporation
822 F.3d 1327 (Federal Circuit, 2016)
Aqua Products, Inc. v. Matal
872 F.3d 1290 (Federal Circuit, 2017)
Maxlinear, Inc. v. Cf Crespe LLC
880 F.3d 1373 (Federal Circuit, 2018)
Berkheimer v. Hp Inc.
881 F.3d 1360 (Federal Circuit, 2018)
Solutran, Inc. v. Elavon, Inc.
931 F.3d 1161 (Federal Circuit, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
GREE, INC v. SUPERCELL OY, Counsel Stack Legal Research, https://law.counselstack.com/opinion/gree-inc-v-supercell-oy-txed-2020.